伴有基因融合且完全缓解的转移性成人Xp11.2易位肾细胞癌
Metastatic adult Xp11.2 translocation renal cell carcinoma with gene fusion in complete remission.
作者信息
Manogna Dharmini, Tenneti Divya, Kramer Zachary
机构信息
Department of Internal Medicine, Rochester General Hospital, Rochester, New York.
Vydehi Institute of Medical Science and Research Center, Bangalore, India.
出版信息
Proc (Bayl Univ Med Cent). 2020 Dec 14;34(2):299-301. doi: 10.1080/08998280.2020.1847946.
Abstract
Xp11 translocation renal cell carcinoma (RCC) accounts for most pediatric cases of RCC but is uncommon in adults. It has an aggressive course in adults with poor response to chemoradiation. We describe a 64-year-old man with Xp11 translocation RCC who achieved complete remission following surgery and chemoimmunotherapy.
摘要
Xp11易位性肾细胞癌（RCC）占小儿RCC的大多数病例，但在成人中并不常见。它在成人中病程进展迅速，对放化疗反应不佳。我们描述了一名64岁患有Xp11易位性RCC的男性患者，其在手术及化疗免疫治疗后实现了完全缓解。
相似文献
1
Metastatic adult Xp11.2 translocation renal cell carcinoma with gene fusion in complete remission.伴有基因融合且完全缓解的转移性成人Xp11.2易位肾细胞癌
Proc (Bayl Univ Med Cent). 2020 Dec 14;34(2):299-301. doi: 10.1080/08998280.2020.1847946.
2
Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.Xp11.2 易位/TFE3 基因融合相关性成人肾细胞癌的超声造影表现：与透明细胞肾细胞癌和乳头状肾细胞癌的比较。
Cancer Imaging. 2019 Dec 31;20(1):1. doi: 10.1186/s40644-019-0268-7.
3
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.TFE3融合变异分析确定了Xp11易位性癌症之间特定的临床病理关联。
Am J Surg Pathol. 2016 Jun;40(6):723-37. doi: 10.1097/PAS.0000000000000631.
4
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.TFE3 断裂分离 FISH 检测与 TFE3 或组织蛋白酶 K 免疫组化染色单独检测相比，对 Xp11.2 易位相关性肾细胞癌具有更高的敏感性：扩大形态学谱。
Am J Surg Pathol. 2013 Jun;37(6):804-15. doi: 10.1097/PAS.0b013e31827e17cb.
5
Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report.伴有TFE3基因融合的Xp11.2易位性肾细胞癌：一例报告
Mol Clin Oncol. 2018 Jan;8(1):83-85. doi: 10.3892/mco.2017.1497. Epub 2017 Nov 13.
6
Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.新设计的断裂分离和ASPL-TFE3双融合荧光原位杂交检测法在诊断Xp11.2易位性肾细胞癌和ASPL-TFE3肾细胞癌中具有应用价值：一篇遵循STARD规范的文章
Medicine (Baltimore). 2015 May;94(19):e873. doi: 10.1097/MD.0000000000000873.
7
Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.Xp11.2 易位性肾肿瘤，具有 TFE3 重排相关肾细胞癌和 Xp11 易位性肾间叶肿瘤伴黑色素细胞分化特征，携带 NONO-TFE3 融合基因。
Pathol Res Pract. 2019 Sep;215(9):152521. doi: 10.1016/j.prp.2019.152521. Epub 2019 Jun 27.
8
The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.沙特成年肾癌患者中与Xp11.2易位/TFE3基因融合相关的肾细胞癌发病率：一项回顾性组织芯片分析
Pol J Pathol. 2018;69(4):376-383. doi: 10.5114/pjp.2018.81697.
9
Four years of natural progressive course: A rare case report of juvenile Xp11.2 translocations renal cell carcinoma with gene fusion.四年自然病程：一例罕见的伴有基因融合的青少年Xp11.2易位性肾细胞癌病例报告
Open Med (Wars). 2024 Jun 29;19(1):20240985. doi: 10.1515/med-2024-0985. eCollection 2024.
10
Cardiopulmonary bypass-assisted surgery for the treatment of Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a tumor thrombus within the inferior vena cava: A case report.体外循环辅助手术治疗合并下腔静脉瘤栓的Xp11.2易位/TFE3基因融合肾细胞癌1例报告
Oncol Lett. 2015 Dec;10(6):3532-3534. doi: 10.3892/ol.2015.3739. Epub 2015 Sep 24.
引用本文的文献
1
Case - Long-term remission after repeated courses of palliative radiotherapy in a patient with metastatic MiT family translocation renal cell carcinoma.病例——转移性MiT家族易位性肾细胞癌患者经多次姑息性放疗后的长期缓解
Can Urol Assoc J. 2024 Sep;18(9):E298-E300. doi: 10.5489/cuaj.8771.
2
Transcription factor E3 renal cell carcinoma presenting as secondary hypertension.表现为继发性高血压的转录因子E3肾细胞癌。
Curr Urol. 2023 Mar;17(1):58-61. doi: 10.1097/CU9.0000000000000108. Epub 2022 Aug 2.
本文引用的文献
1
Nephron-sparing surgery in the treatment of pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions.保留肾单位手术治疗与Xp11.2易位/TFE3基因融合相关的儿童肾细胞癌
J Pediatr Surg. 2017 Sep;52(9):1492-1495. doi: 10.1016/j.jpedsurg.2017.03.052. Epub 2017 Mar 27.
2
Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.与Xp11.2易位/TFE3基因融合相关的肾细胞癌：临床特征、治疗与预后
PLoS One. 2016 Nov 28;11(11):e0166897. doi: 10.1371/journal.pone.0166897. eCollection 2016.
3
Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.与Xp11.2易位/TFE3基因融合相关的肾细胞癌：临床经验及文献综述
Future Oncol. 2015;11(24):3243-52. doi: 10.2217/fon.15.177. Epub 2015 Jul 14.
4
Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect.Xp11.2 易位/TFE3 基因融合相关性肾细胞癌的研究进展：聚焦于病理生物学方面
Histol Histopathol. 2012 Feb;27(2):133-40. doi: 10.14670/HH-27.133.
5
Xp11 translocation renal cell carcinoma.Xp11 易位性肾细胞癌。
Pathology. 2010 Jun;42(4):369-73. doi: 10.3109/00313021003767348.
6
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.转移性 Xp11 易位/TFE3 基因融合肾细胞癌（RCC）中的靶向药物：来自青少年 RCC 网络的报告。
Ann Oncol. 2010 Sep;21(9):1834-1838. doi: 10.1093/annonc/mdq029. Epub 2010 Feb 12.
7
Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.通过细胞遗传学和免疫组织化学诊断的成人Xp11易位性肾细胞癌
Clin Cancer Res. 2009 Feb 15;15(4):1170-6. doi: 10.1158/1078-0432.CCR-08-1183.
8
Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.易位性肾细胞癌：淋巴结转移无负面影响。
Cancer. 2008 Apr 1;112(7):1607-16. doi: 10.1002/cncr.23331.
9
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum.成人Xp11易位性肾细胞癌：临床、病理及基因谱的扩展
Am J Surg Pathol. 2007 Aug;31(8):1149-60. doi: 10.1097/PAS.0b013e318031ffff.
10
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.TFE3 融合蛋白通过转录上调激活 MET 信号通路，从而将另一类肿瘤定义为 MET 抑制治疗的候选对象。
Cancer Res. 2007 Feb 1;67(3):919-29. doi: 10.1158/0008-5472.CAN-06-2855.
Zotero 插件